Home / Products / Dermatology Portfolio / Treat skin infection

Print page content Print
Increase text size Decrease text size
Text Size

Treat skin infection

Treat skin infection

Skin infection can disrupt the pet-owner connection—protect the bond with CONVENIA® Convenia

Continue APOQUEL® and treat with CONVENIA if you identify a Staph pyoderma due to allergic dermatitis

  • First-time treatment success
    • 86% of dogs needed just 1 injection to resolve their skin infection in a US efficacy study1
    • Dosing simplifies life for clients, eliminates compliance challenges and gives you peace of mind so you can focus on other areas of the diagnostic workup
  • Fast-acting, a single SQ injection provides rapid and complete absorption for resolution of baterial skin infections1
  • 100% compliance—assured treatment in a single injection

(–

A single injection provides antibiotic treatment for up to 14 days*

CONVENIA single injection

Gunner’s story2

  • 12-year-old male Golden Retriever
  • Gunner developed a severe allergy, which quickly escalated to a large, distressing hot spot that alarmed his owner
  • Gunner was diagnosed with pyoderma secondary to allergic dermatitis and given CONVENIA for the infection and a first dose of APOQUEL for the itch while he was still in the clinic
  • Within 24 hours, Gunner had stopped scratching and rolling on the floor and was lively and playful again
Gunner’s pyoderma before APOQUEL and CONVENIA
Before
Gunner’s pyoderma after APOQUEL and CONVENIA
Day 4

Relief protects the bond

APOQUEL and CONVENIA are the new standard of care, in my opinion. With the anti-itch therapy as well as the antibiotic therapy, you’re taking care of both conditions at the same time very effectively and quickly.

John Hutchens, DVM

TAILOR YOUR APPROACH WITH INDIVIDUALIZED CARE

CYTOPOINT® is a great option during allergic flares when bacterial infections are present and administration of oral medication is a challenge

Next, Conduct Food Trial

Learn more at CONVENIA.COM

In clinical studies, a single injection of CONVENIA was clinically equivalent to a 14-day antibiotic regimen.

CONVENIA INDICATIONS: CONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

CONVENIA IMPORTANT SAFETY INFORMATION: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to CONVENIA. Do not use in dogs or cats with a history of allergic reactions to penicillins or cephalosporins. Side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia, and lethargy.

For more information, please see the full Prescribing Information.

APOQUEL Indications: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

APOQUEL IMPORTANT SAFETY INFORMATION: Do not use APOQUEL® (oclacitinib tablet) in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

SIMPARICA TRIO INDICATIONS: SIMPARICA TRIO is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina) and adult hookworm (Ancylostoma caninum and Uncinaria stenocephala) infections. SIMPARICA TRIO kills adult fleas (Ctenocephalides felis) and is indicated for the treatment and prevention of flea infestations, and the treatment and control of tick infestations with Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick) for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater.

SIMPARICA TRIO IMPORTANT SAFETY INFORMATION: Use with caution in dogs with a history of seizures. SIMPARICA TRIO contains sarolaner, a member of the isoxazoline class, which has been associated with neurologic adverse reactions including tremors, ataxia, and seizures in dogs with or without a history of neurologic disorders. The safe use of SIMPARICA TRIO has not been evaluated in breeding, pregnant, or lactating dogs. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.

For more information, please see the full Prescribing Information.

CYTOPOINT INDICATIONS: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

References: 1. Six R, Cherni J, Chesebrough R, et al. Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses, or infected wounds in dogs. J Am Vet Med Assoc. 2008;233(3):433-439. 2. Data on file, Pet Owner Cases—Bijou, Gunner, Nani, Captain and Molly, Zoetis Inc.

Testimonials represent individual experience only and the experiences and opinions herein may be unique to the patient and the speaker. Individual results may vary, considering the unique characteristics of the patient.

This site is intended for U.S. Animal Healthcare Professionals. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. NexGard is a trademark of the Boehringer Ingelheim group.
© 2021 Zoetis Services LLC. All rights reserved. ZPC-00064R4

×

CONTACT US

1-888-963-8471

Mon–Fri, 8:30am–8:00pm ET

zoetis logo United States flag United States

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.